CHINESE JOURNAL OF MEDICINAL GUIDE >

2026 , Vol. 28 >Issue 6: 745 - 745-750

DOI: https://doi.org/10.1009-0959.2026.080005

Operation Exploration and Practice of the Remote Monitoring Platform for Clinical Trials

Expand
  • 1.National Institution for Drug Cinical Trial， Nanfang Hospital， Southern Medical University，
    Guangdong Guangzhou 510515， China；
    2.New Trials Medical Technology （Hangzhou） Co.， Ltd.， Zhejiang Hangzhou 310000， China

Received date: 2025-11-28

  Revised date: 2026-04-17

  Accepted date: 2026-06-28

  Online published: 2026-08-17

Fold

Abstract

 In recent years， the implementation paradigm and regulatory model of clinical trials have undergone a major transformation from on-site to remote online. By leveraging digital and intelligent technologies， clinical trial institutions can break through development bottlenecks， which not only improves the efficiency of whole-process management in clinical trials to achieve quality improvement and efficiency enhancement， but also lays a foundation for medical institutions to build differentiation， control risks， ensure quality， and enhance core competitiveness. Decentralized clinical trials （DCT）， remote monitoring of clinical trials， and other approaches have become new intelligent and normalized models for clinical trial operation and management. Such applications have reached a certain scale in China， and relevant practical consensus has been continuously issued. To present the advantages of digital intelligence such as "data visualization， risk controllability， and quality verifiability"， and to further provide empirical references and guidance for the implementation and optimization of digital intelligence supervision in remote monitoring of clinical trials in China， this study takes the operational practice of the remote monitoring platform for clinical trials in the Southern Hospital of Southern Medical University as a case. Based on the review of the technical requirements and architecture for the construction of remote monitoring platforms， this study explores the management path of remote monitoring， analyzing the implementation benefits of remote monitoring， including： significantly reducing clinical trial operational costs， effectively optimizing monitoring work hours allocation and time utilization， improving monitoring work quality， and achieving green and low-carbon benefits. This study puts forward relevant suggestions for the problems identified： a complete data tracing chain can be formed by constructing a source data index map， establish unified document naming and classification rules to ensure standardized management of document strengthen the management of the remote monitoring platform through permission control and trajectory monitoring to standardize operation management， with the help of remote monitoring platform to collaborate the quality management of multi-campus public hospitals， to practice a new model of high-quality and efficient clinical trial operation and management.


Key words：  ; Clinical trials； ; Remote monitoring platform； ; Digital and intelligent supervision and management； ; Regulatory science

Cite this article

ZHENG Qingsi, XU Keqiang, LU Yichao, SU Aishan, XU Zhongyuan .

Operation Exploration and Practice of the Remote Monitoring Platform for Clinical Trials

[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2026 , 28(6) : 745 -745-750 . DOI: 10.1009-0959.2026.080005

References

    ［1］ 周凤，甘晨曦，徐亚文，等.去中心化临床试验应用现状［J］.南昌大学学报（医学版），2023，63（2）：88-92.

         ［2］  FDA. FDA patient-focused drug development Guidance series for eEnhancing the incorporationof the patient's voice in medical product development and regulatory decision making［EB/OL］.（2025-10-23）［2025-11-07］.https：//www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical.

         ［3］  刘懿贤，游佳，邸相杰，等.去中心化临床试验（DCT）的创新与探索：华西实践［J］.中国医药导刊，2024，26（8）：774-779.

         ［4］  周文菁，吴敏江，刘少璇，等.非罕见病药物临床试验中去中心化临床试验技术的应用及实施［J］.医药导报，2026，45（1）：161-166.

         ［5］  马润镒，苏娴，王海学，等.美欧监管机构对远程智能临床试验探索的进展［J］.中国食品药品监管，2020，（11）：102-109 .

         ［6］  许重远，元唯安，沈一峰，等.基于源文件查阅的远程监查［J］. 中国临床药理学杂志， 2023，39（9）：1364-1368.

         ［7］  傅志英，刘晓红，赵淑华，等.新药临床试验远程监查实践初析［J］.中国新药杂志，2021，30（3）：209-214.

         ［8］  魏宇梅，余一旻，李妍，等.临床试验远程监查解决方案［J］.中国新药与临床杂志，2022，41（6）：347-351.

         ［9］  陈欢，龚倩，郭雨娇，等.药物临床试验远程监查专家共识（2024年版本）［J］.中国医药导刊，2025，27（2）：191-195.

         ［10］ 国家药品监督管理局药品审评中心.国家药监局药审中心关于发布《以患者为中心的药物临床试验设计技术指导原则（试行）》《以患者为中心的药物临床试验实施技术指导原则（试行）》《以患者为中心的药物获益-风险评估技术指导原则（试行）》的通告（2023年第44号）［EB/OL］.（2023-07-27）［2025-10-09］.https//www.cde.org.cn/main/news/viewInfoCommon/42c008e28f7004cd19b73949142380bd.

         ［11］ 国家药品监督管理局药品审评中心.关于公开征求ICH《E6（R3）：药物临床试验质量管理规范技术指导原则（GCP）》原则及附件1实施建议意见的通知［EB/OL］.（2025-08-28）［2025-10-09］.https：//www.cde.org.cn/main/news/viewInfoCommon/aa3e4b17f74fd27f1589fbcbb3b93f64.

         ［12］ “临床研究能力提升与参与者保护实践”平台.疫情下的临床试验——远程监查平台率先启动［EB/OL］.（2020-02-11）［2025-10-09］.https：//mp.weixin.qq.com/s/7p8MDUhId6Ngu7b8p9fgQw.

         ［13］ 中国药品监督管理研究会，杭州泰格医药科技股份有限公司，北京协同医药医学创新促进中心（CMAC）.2024数字化/去中心化临床试验行业发展现状调研分析报告［EB/OL］.（2025-05-09）［2025-10-09］.https：//pdf.dfcfw.com/pdf/H3_AP202505161673960067_1.pdf？1747578260000.pdf.

         ［14］ 陈欢，陆益超，郭雨娇，等.远程监查在临床试验中的应用与发展趋势［J］.中国医药导刊，2025，27（2）：212-216.

         ［15］ 阴艳丽，徐仁恩.远程监查在药品监管的应用与思考［J］.中国医药导刊，2025，27（9）：878-881.

         ［16］ 国家药品监督管理局，国家卫生健康委员会.国家药监局，国家卫生健康委关于发布药物临床试验质量管理规范的公告［EB/OL］.2020-04-23［2025-10-09］.https：//www.gov.cn/gongbao/content/2020/content_5525106.htm.

         ［17］ 国家药品监督管理局.国家药监局关于发布药物临床试验必备文件保存指导原则的通告（2020年第37号）［EB/OL］.2020-06-03［2025-10-09］.https：//www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20200608094301326.html.

         ［18］ 贾磊，严海泓，刘利军，等.多院区医疗机构临床试验药物管理模式现状调研及探讨［J］.中国医药导刊，2024，26（8）：780-784.

         ［19］ 陈武朝，黄二丹，潘黎，等.公立医院高质量发展背景下多院区同质化面临问题与实现路径［J］.中国医院，2024，28（1）：15-18.

         ［20］ 罗嵇宁，孙搏，李刚.上海市药物临床试验多院区管理现状与监管对策［J］.中国新药与临床杂志，2025，44（10）：727-733.

Options
Outlines

/

〈 〉